Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics, Inc. (FLGT) entered into a lease with EP 63 Kendrick Realty LLC for approximately 44,644 rentable square feet in Needham, Massachusetts, for office, research and development, diagnostic laboratory, light manufacturing and warehouse use. The term is estimated to begin on the earlier of August 1, 2027, or issuance of a final Certificate of Use and Occupancy. The initial monthly base rent is $132,071.83, with annual increases of 3.0%; rent is due 180 days after the term commencement date. The lease ends on the last day of the month 126 months after commencement.
Fulgent may extend the term for two successive five-year periods at fair market rent. The landlord will provide a tenant-improvement allowance of up to $100 per rentable square foot. If delivery is delayed beyond certain dates following the January 1, 2027 target, the lease provides for rent abatement and, if the delay continues for more than 90 days, a termination right, subject to the lease terms. Fulgent is providing a $792,431 cash security deposit, subject to reduction if certain conditions are met, and is responsible for specified repairs and services and its share of operating costs.
Fulgent Genetics, Inc. (FLGT) reported third-quarter 2026 revenue of $90.4 million, compared with $84.1 million in 2025, and a net loss attributable to Fulgent of $13.2 million versus $6.6 million. Operating loss was $22.5 million, compared with $15.4 million. For the first nine months, revenue was $246.9 million versus $239.3 million, while net loss attributable to Fulgent was $67.5 million versus $37.1 million.
Net cash provided by operating activities was $92.6 million in the first nine months of 2026, compared with $23.5 million used in 2025. At September 30, cash and cash equivalents were $86.8 million, and available-for-sale debt securities had a fair value of $565.5 million. Fulgent repurchased $64.1 million of common stock during the nine-month period. The Bako acquisition closed on March 17, 2026, and its operations are included in laboratory services. Fulgent wrote off $12.3 million of receivables during the nine months, substantially all related to institutional receivables from its COVID-19 testing business, which it ceased in 2023; the balances had been previously reserved, and collection efforts were exhausted.
Fulgent Genetics, Inc. (FLGT) reported third-quarter 2026 revenue of $90.4 million, up approximately 8% year over year. Net loss attributable to Fulgent was $13.2 million, or $0.48 per share, versus $6.6 million, or $0.21 per share, a year earlier. Non-GAAP loss was $2.4 million, or $0.09 per share, versus non-GAAP income of $4.5 million; GAAP gross margin was 35.3%, versus 42.2%, and adjusted EBITDA was a $7.5 million loss, versus $0.7 million income.
Cash, cash equivalents, restricted cash and investments in marketable securities totaled $652.4 million at September 30, 2026. For full-year 2026, Fulgent maintains revenue guidance of $330.0 million to $340.0 million and now expects a non-GAAP loss of approximately $46.0 million to $50.0 million and cash, cash equivalents, restricted cash and investments in marketable securities of approximately $630.0 million. The outlook reflects 4.1 million shares repurchased and $64.1 million of repurchase spending through September 30; the cash estimate assumes $13 million in capital purchases, no further near-term repurchases and $21 million in therapeutic-development spending.
Fulgent Genetics, Inc. (FLGT) reported that Chief Scientific Officer Hanlin Gao had 1,645 common shares withheld on October 26, 2026, to satisfy tax-withholding obligations arising upon vesting of certain restricted stock units. The reported price was $20.22 per share. Gao reported direct holdings of 984,472 shares following the transaction.
Fulgent Genetics, Inc. President and COO Jian Xie had 4,361 shares withheld on October 26, 2026, to satisfy tax withholding obligations upon vesting of certain restricted stock units; the reported price was $20.22 per share. His direct holdings after the transaction were 355,563 shares. Separately, 220,816 shares were held by The Hsieh Family Dynasty Trust.
Fulgent Genetics, Inc. CFO and Treasurer Paul Kim had 2,748 shares of common stock withheld on October 26, 2026, to satisfy tax withholding obligations arising upon vesting of certain restricted stock units. The reported price was $20.22 per share, and Kim’s direct holdings after the transaction were 353,795 shares. The awards were assumed pursuant to an Agreement and Plan of Merger dated November 7, 2022.
Fulgent Genetics, Inc. (FLGT) reported that its CFO and Treasurer, Paul Kim, had 2,087 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 25, 2025. After this tax-withholding disposition, Kim directly holds 356,543 shares of Fulgent Genetics common stock.
Fulgent Genetics, Inc. (FLGT) reported that Chief Executive Officer and director Ming Hsieh had 4,392 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 25, 2025. After this tax-withholding disposition, he directly holds 885,952 shares of common stock. He also reports indirect ownership through the Ming Hsieh Trust, the Dynasty Trust (for which he disclaims any beneficial interest except for any pecuniary interest), a Uniform Transfers to Minors Act account, and an immediate family member’s account, where he or related parties have varying voting and dispositive powers. No Rule 10b5-1 trading plan is reported for these transactions.
Fulgent Genetics, Inc. (FLGT) reported that Chief Scientific Officer Hanlin Gao sold 1,673 shares of common stock on September 2, 2026 at a weighted-average price of $19.66 per share. According to the disclosure, the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units. Following this sale, Gao directly holds 986,117 shares of Fulgent Genetics common stock.
Fulgent Genetics, Inc. (FLGT) reports that President and COO Jian Xie sold 2,127 shares of common stock on September 2, 2026 at a weighted-average price of $19.6564 per share to satisfy tax withholding obligations arising from vesting of previously granted restricted stock units. Following this sale, he directly holds 359,924 shares and has indirect ownership of 220,816 shares held by The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.